Synergistic Wound Healing Enhancement by Extracellular Vesicles From Engineered Macrophages and Fibroblasts
Journal of Biomedical Materials Research Part A · 2026
DOI: 10.1002/jbm.a.70126 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biomedical Materials Research Part A, 2026. Verfasst von Ping Liang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Fuzhou University Affiliated Provincial Hospital, Fuzhou University, Fuzhou, China. Hauptthemen laut MEDLINE: Wound Healing, Fibroblasts, Macrophages, Extracellular Vesicles. Die Arbeit nennt 53 Literaturangaben. Gefördert von: Joint Funds for the Innovation of Science and Technology, Natural Science Foundation of Fujian Province, National Natural Science Foundation of China.
Themen: Wundversorgung
Abstract (Originalsprache)
Severe wound healing impairment risks persistent tissue damage and even necrosis. Cell‐free exosome therapy demonstrates significant potential in wound healing due to its high efficacy and micro‐volume characteristics. However, its clinical‐scale translation faces challenges including low yield, limited sources, functional monotony, and low bioavailability. We developed a lentiviral co‐engineering strategy introducing exosome secretion‐related genes into macrophage and fibroblast cell lines, achieving stable, high‐yield (twofold increase) exosome production. Co‐engineered extracellular vesicles (EVs) demonstrated enhanced cellular uptake and synergistically upregulated pro‐angiogenic ( HIF‐1α , VEGF‐A ) and anti‐inflammatory ( IL‐4 , IL‐10 ) factors. In a cell model and murine full‐thickness wound model, the combination of EVs from both sources potently accelerated healing, promoting re‐epithelialization and collagen deposition while orchestrating an anti‐inflammatory response via TNF‐α / IL‐1β downregulation and IL‐10 upregulation. In summary, co‐cultured EVs not only exhibit high yield and purity but also demonstrate potent pro‐angiogenic, anti‐inflammatory, and antioxidant effects, effectively promoting wound healing, epithelial tissue regeneration, and collagen deposition. This study proposes an innovative and highly efficient method for synergistically regulating the production of EVs from cellular systems, providing promising research resources for their application in wound healing and medical esthetics. It also offers crucial insights for investigating the underlying mechanisms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Fuzhou University Affiliated Provincial Hospital, Fuzhou University, Fuzhou, China.
- College of Biological Science and Engineering, Fuzhou University, Fuzhou, Fujian, China.
- Department of Cardiology, Shengli Clinical Medical College of Fujian Medical University, Fuzhou University Affiliated Provincial Hospital, Fujian Provincial Hospital, Fujian Provincial Key Laboratory of Cardiovascular D…
- School of Medicine, Fuzhou University, Fuzhou, China.
ORCID-Profile: Zuquan Weng
Förderung
- Joint Funds for the Innovation of Science and Technology
- Natural Science Foundation of Fujian Province
- National Natural Science Foundation of China
Zitieren
APA
Liang, P., Ye, J., Lin, K., Luo, Q., Zheng, H., Hu, Y., Zou, M., Huang, Y., Wu, S., Sun, Q., Guo, Y., & Weng, Z. (2026). Synergistic Wound Healing Enhancement by Extracellular Vesicles From Engineered Macrophages and Fibroblasts. Journal of Biomedical Materials Research Part A. https://doi.org/10.1002/jbm.a.70126
Vancouver
Liang P, Ye J, Lin K, Luo Q, Zheng H, Hu Y, et al. Synergistic Wound Healing Enhancement by Extracellular Vesicles From Engineered Macrophages and Fibroblasts. Journal of Biomedical Materials Research Part A. 2026. doi:10.1002/jbm.a.70126
BibTeX
@article{Liang2026,
author = {Liang, Ping and Ye, Jialin and Lin, Kaiyang and Luo, Qinghua and Zheng, Haisu and Hu, Yuyao and Zou, MingLang and Huang, Yanting and Wu, Sifang and Sun, Qi and Guo, Yansong and Weng, Zuquan},
title = {Synergistic Wound Healing Enhancement by Extracellular Vesicles From Engineered Macrophages and Fibroblasts},
journal = {Journal of Biomedical Materials Research Part A},
year = {2026},
doi = {10.1002/jbm.a.70126}
}
EUVIMED